WO2011158815A1 - Method for simultaneous achievement of bacteriolysis of acid-fast bacterium and separation of nucleic acid from the bacterium - Google Patents
Method for simultaneous achievement of bacteriolysis of acid-fast bacterium and separation of nucleic acid from the bacterium Download PDFInfo
- Publication number
- WO2011158815A1 WO2011158815A1 PCT/JP2011/063555 JP2011063555W WO2011158815A1 WO 2011158815 A1 WO2011158815 A1 WO 2011158815A1 JP 2011063555 W JP2011063555 W JP 2011063555W WO 2011158815 A1 WO2011158815 A1 WO 2011158815A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- mixed solution
- fast
- bacterium
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
Definitions
- the present invention relates to a method for simultaneously performing lysis of acid-fast bacteria typified by Mycobacterium tuberculosis and separation of its nucleic acids by simple operations.
- Tuberculosis is a bacterial disease that is showing signs of rebirth in Japan, and improvement of its diagnostic method is extremely important.
- a genetic test that can obtain highly accurate results in a short time has been carried out instead of a culture test that takes several weeks.
- Tuberculosis genetic testing is performed by identifying the presence of M. tuberculosis in sputum samples by PCR using primers specific to the M. tuberculosis gene.
- PCR primers specific to the M. tuberculosis gene.
- acid-fast bacteria typified by Mycobacterium tuberculosis have a strong cell wall including a lipid layer of mycolic acid, and are therefore difficult to lyse compared with general bacteria such as Escherichia coli.
- Patent Document 1 As a general lysis method of acid-fast bacteria, a method of physically destroying bacterial cells using ultrasonic waves (see Patent Document 1), a method of destroying bacterial cells using phenol as a lysis agent, 60 A method of lysing acid-fast bacteria by heating to ⁇ 100 ° C. (see Patent Document 2).
- the present invention was devised in view of the current state of the prior art, and an object of the present invention is to provide a method capable of efficiently simultaneously lysing mycobacterial lysis and its nucleic acid with a simple operation. It is in.
- the present inventor first brought an acid-fast bacterium into contact with a chaotropic salt to soften the cell wall of the bacterium, and this was then passed through a pore structure continuum having a specific pore size. By repeatedly passing the cells, the cell wall was efficiently destroyed, and it was found that lysis of acid-fast bacteria and separation of nucleic acids could be performed simultaneously, and the present invention was completed.
- the present invention has the following configurations (1) to (6).
- (1) Prepare a mixed solution containing a chaotropic salt and acid-fast bacteria, and then repeat the suction and discharge of the mixed solution using a chip in which a pore structure continuous body having a pore size of 10 to 100 ⁇ m is welded.
- a method comprising simultaneously lysing acid-fast bacilli and separating nucleic acids thereof.
- (2) The method according to (1), wherein the concentration of the chaotropic salt in the mixed solution is 2 to 6M.
- (3) The method according to (1) or (2), wherein the pH of the mixed solution is 4.5 to 6.5.
- the acid-fast bacterium having a cell wall softened with a chaotropic salt is repeatedly passed through a chip in which a continuous pore structure having a specific pore size is welded. Lysis and its nucleic acid can be separated easily and efficiently at the same time.
- the method of the present invention uses acid-resistant bacteria lysis by repeating suction and discharge of a mixed solution containing a chaotropic salt and acid-fast bacteria using a chip in which a continuous pore structure having a specific pore size is welded.
- the nucleic acids are separated at the same time.
- Examples of acid-fast bacteria to be lysed by the method of the present invention include Mycobacterium avium, M. intracellulare, M. gordonae, and M. tuberculosis. (M. tuberculosis), M. kansasii, M. fortuitum, M. chelonae, M. bovis, M. scroflace. ), M. paratuberculosis, M. phlei, M. marinum, M. simiae, M. scraceum (M. scr). fulaceum, M. szulgai, M. leprae, M. xenopi, M. ulcerans, M. lepraemurium, M. flavescens (M.
- thermo register table M.thermoresistable
- M. smegmatis M. smegmatis
- the chaotropic salt used in the method of the present invention is a chemical substance that has the property of destabilizing molecular structures such as proteins, and is used as a lysing agent for lysing cells during nucleic acid extraction in the field of biochemistry. It is a substance. Any conventionally known chaotropic salt can be used, such as guanidine salt, sodium isothiocyanate, sodium iodide, potassium iodide, urea, sodium bromide, potassium bromide, calcium bromide, bromide. It can be ammonium, sodium perchlorate, sodium thiocyanate, potassium thiocyanate, ammonium isothiocyanate, sodium chloride, potassium chloride, ammonium chloride.
- guanidine salt is preferable in terms of cell solubility and nucleic acid recovery efficiency.
- the guanidine salt include guanidine hydrochloride, guanidine thiocyanate (guanidine thiocyanate), guanidine sulfate, and guanidine isothiocyanate.
- guanidine hydrochloride or guanidine thiocyanate is preferable from the viewpoint of lysis efficiency.
- the acid-fast bacterium and the chaotropic salt are used in the form of a mixed solution containing both, and can be easily prepared into a mixed solution by dissolving the chaotropic salt and the acid-fast bacterium in an appropriate solvent such as water or a buffer solution.
- a mixed solution can be prepared by dissolving a chaotropic salt and a buffering agent in deionized water and adding a bacterial solution in which acid-fast bacteria are prepared at a constant concentration.
- the concentration of the chaotropic salt in the mixed solution is preferably 2 to 6 M (mol / L), more preferably 3 to 5 M (mol / L). If the concentration of the chaotropic salt in the mixed solution is less than the lower limit, the lysis efficiency of the acid-fast bacterium cell wall may be reduced, and if it exceeds the upper limit, the chaotropic salt may be precipitated.
- the pH of the mixed solution is preferably 4.5 to 6.5, more preferably 5.0 to 6.0. If the pH of the mixed solution is less than the above lower limit or exceeds the above upper limit, the nucleic acid separation efficiency may be lowered.
- an appropriate buffer to the solution.
- An example of such a buffering agent is acetate.
- acetates monovalent metal acetates such as potassium acetate and sodium acetate are particularly effective.
- the concentration of these acetates in the mixed solution is preferably 0.1 to 1.0 M (mol / L) from the viewpoint of the buffering effect.
- MES MES (2-morpholinoethanesulfonic acid
- ACES N- (2-acetamido) -2-aminoethanesulfonic acid
- PIPES piperazine-1,4-bis (2) -Good buffer solutions having a buffer capacity on the acidic side, such as ethanesulfonic acid
- concentration of these Good buffers in the mixed solution is preferably 0.05 to 0.5 M (mol / L) from the viewpoint of the buffering effect.
- a mixed solution containing a chaotropic salt and an acid-fast bacterium can be used as it is at room temperature, but it is preferable to use it after heating to a specific temperature.
- the heating temperature is 35 to 80 ° C., preferably 40 to 75 ° C.
- the dissolution effect of the chaotropic salt is likely to be improved, but if the heating temperature is too high, the evaporation of the liquid increases and the concentration of the chaotropic salt may change.
- the nucleic acid adsorption ability to the pore structure continuum may be reduced.
- the heating method is not particularly limited, and examples thereof include a method in which the mixed solution is put in an appropriate tube and heated by a known heating means such as a heat block, a water bath, a microwave oven, or an air bath.
- a known heating means such as a heat block, a water bath, a microwave oven, or an air bath.
- the acid-fast bacterium may be added to the mixed solution from the beginning, or may be added after the mixed solution is heated to a predetermined temperature.
- the method of the present invention uses the tip having a pore structure continuous body having a pore diameter of 10 to 100 ⁇ m welded therein to repeatedly suck and discharge the above mixed solution, whereby the acid-fast bacteria and the pore structure continuous body are The pores are in contact with each other, and not only the acid-fast bacteriolysis but also the nucleic acid separation is performed at the same time.
- FIG. 1 shows a schematic diagram of an example of the structure of a chip used in the method of the present invention.
- the chip 1 used in the present invention basically has a conventionally known configuration (for example, an elongated inverted conical hollow body shown in FIG. 1), and the inside thereof has a pore structure continuous body over a certain length from the tip. 2 is welded.
- the pore structure continuum has a continuous pore structure, and the pore diameter is 10 to 100 ⁇ m, preferably 20 to 70 ⁇ m. If the pore diameter deviates from the above range, acid-fast bacteria lysis and nucleic acid separation cannot be performed effectively.
- the material of the pore structure is not particularly limited, but silica is preferable.
- Monolithic silica has a structure that integrates a three-dimensional network-like framework and pore channels, and can control micro-sized through-holes and nano-sized pores on the framework surface during synthesis.
- the pore structure continuum can generally be produced by a sol-gel method.
- a metal alkoxide is partially hydrolyzed to produce a reactive monomer, and this monomer is polycondensed to produce a colloidal oligomer.
- the pore structure continuous body is shaped into a size accommodated in the chip, and then welded to the chip using, for example, ultrasonic waves.
- the chip with the pore structure continuous body welded inside is attached to a syringe and the like, and repeatedly sucks and discharges the liquid mixture containing the chaotropic salt and acid-fast bacteria.
- the number of repetitions of suction and discharge is preferably 3 times or more. If it is less than 3 times, there is a possibility that acid-fast lysis and nucleic acid cannot be sufficiently separated. There is no upper limit to the number of repetitions, but a maximum of about 20 is sufficient.
- Example 1 Preparation of acid-fast bacterium
- the Mycobacterium bovis BCG strain (hereinafter abbreviated as BCG strain) was used.
- the BCG strain was cultured in 3% Ogawa medium (Nissui Pharmaceutical Co., Ltd.) at 35 ° C. for 2 weeks, then inoculated into MycoBroth (manufactured by Kyokuto Pharmaceutical Co., Ltd.), a liquid medium for acid-fast bacteria culture, and at 37 ° C. for 6 days. Further culture was performed.
- the cultured liquid medium was filtered with a hydrophilic filter having a pore size of 5 ⁇ m, and then the concentration of McFarland 1 was measured according to the McFarland turbidimetric method while measuring OD600 with a turbidimeter. The bacterial solution was adjusted.
- 1.0 mL of this bacterial solution is added to a 1.5 mL tube, and only bacterial cells are precipitated by centrifugation, and the supernatant is removed to remove 1
- the cells were resuspended with 0 mL of phosphate buffer.
- the tip was moved to a tube containing 500 ⁇ L of the cleaning solution, and the cleaning solution was sucked and discharged three times at a rate of 100 ⁇ L / second for cleaning. This washing process was repeated once more. Finally, the tip is moved to a tube containing 100 ⁇ L of eluate, and the eluate is aspirated and discharged 5 times at a rate of 100 ⁇ L / sec to elute the acid-fast bacilli nucleic acids adsorbed on the continuous pore structure in the chip. did. In order to suppress a decrease in elution efficiency, care was taken so that air did not contact the continuous pore structure in the chip during suction and discharge. Note that a 0.8 M potassium acetate solution in 70% ethanol was used as the washing solution, and a 10 mM potassium hydroxide aqueous solution was used as the eluent.
- Reagent composition Oligo 1 250 nM, Oligo 2 1500 nM, Oligo 3 (5 ′ end labeled with BODIPY-FL) 250 nM, ⁇ 10 buffer 1 ⁇ L, dNTP 0.2 mM, MgSO 4 4 mM, KOD plus DNA polymerase 0.2U, Eluate 1 ⁇ L (Adjust the total volume to 10 ⁇ L with Milli-Q water) (The sequences of Oligo 1 to Oligo 3 are as shown in SEQ ID Nos. 1 to 3 in the sequence listing.)
- PCR conditions Thermal denaturation: 94 ° C for 2 minutes, 98 ° C for 0 seconds, annealing: 60 ° C for 5 seconds (fluorescence detection), 50 cycles
- the above reagent composition is a combination of a primer and a probe that can specifically detect the BCG strain.
- genomic DNA extracted from the BCG strain by the phenol / chloroform method was diluted with 10 mM Tris buffer so as to contain 1000 copies in 1 ⁇ L.
- Real-time PCR detects a specific nucleic acid sequence in a sample based on the fact that the fluorescence of a fluorescent dye labeled on the probe is quenched when the amplification product and the probe are hybridized.
- a light cycler (registered trademark) manufactured by Roche Diagnostics was used for amplification and detection of nucleic acids.
- the measurement mode 530 nm was used, and the obtained QProbe extinction ratio was calculated using the obtained real-time detection data. Furthermore, the number of cycles that reached a quenching rate of 2% was determined and analyzed in the same manner as the real-time quantitative PCR method using SYBR Green I.
- the nucleic acid recovery efficiency of mycobacteria was expressed as a percentage relative to 100% positive control. In addition, it is considered that the nucleic acid recovery efficiency of acid-fast bacteria is good if it is 30% or more. The results are shown in Table 1.
- Example 2 The mixture obtained in (3) was put into a 1.5 mL tube with a screw cap and heated and heated at 65 ° C. for 5 minutes on a heat block, except that suction and discharge were performed in (4). In the same manner as in Example 1, the nucleic acid recovery efficiency of acid-fast bacteria was displayed. The results are shown in Table 1.
- Example 3 The recovery efficiency of acid-fast bacilli nucleic acids was displayed in the same manner as in Example 2 except that the pore diameter of the pore structure continuum of (4) was changed to 10 ⁇ m. The results are shown in Table 1.
- Example 4 The recovery efficiency of acid-fast bacterium nucleic acids was displayed in the same manner as in Example 2 except that the pore diameter of the pore structure continuum in (4) was changed to 20 ⁇ m. The results are shown in Table 1.
- Example 5 The recovery efficiency of acid-fast bacterium nucleic acids was displayed in the same manner as in Example 2 except that the pore diameter of the pore structure continuum in (4) was changed to 40 ⁇ m. The results are shown in Table 1.
- Example 6 The nucleic acid recovery efficiency of acid-fast bacteria was displayed in the same manner as in Example 2 except that the pore diameter of the pore structure continuous body of (4) was changed to 50 ⁇ m. The results are shown in Table 1.
- Example 7 The recovery efficiency of acid-fast bacilli nucleic acids was displayed in the same manner as in Example 2 except that the pore diameter of the pore structure continuum in (4) was changed to 70 ⁇ m. The results are shown in Table 1.
- Example 8 The efficiency of acid-fast bacilli nucleic acid recovery was displayed in the same manner as in Example 2, except that guanidine hydrochloride was used in place of guanidine thiocyanate as the chaotropic salt. The results are shown in Table 1.
- Example 9 The recovery efficiency of the acid-fast bacterium's nucleic acid was displayed in the same manner as in Example 2 except that the number of suction / discharge in the process of lysis of the acid-fast bacterium and the separation of the nucleic acid was changed to 5. The results are shown in Table 1.
- Example 10 The recovery efficiency of acid-fast bacilli nucleic acids was displayed in the same manner as in Example 2 except that the number of suction / discharge in the acid-fast bacilli lysis and nucleic acid separation steps was changed to 20. The results are shown in Table 1.
- Example 11 The recovery efficiency of the acid-fast bacterium nucleic acid was displayed in the same manner as in Example 2 except that the heating temperature was changed to 40 ° C. The results are shown in Table 1.
- Example 12 The recovery efficiency of acid-fast bacilli nucleic acids was displayed in the same manner as in Example 2 except that the heating temperature was changed to 75 ° C. The results are shown in Table 1.
- Example 13 The recovery efficiency of acid-fast bacterium nucleic acids was displayed in the same manner as in Example 2 except that the heating temperature was changed to 95 ° C. The results are shown in Table 1.
- Comparative Example 1 The nucleic acid recovery efficiency of acid-fast bacteria was displayed in the same manner as in Example 2 except that the pore diameter of the pore structure continuous body of (4) was changed to 120 ⁇ m. The results are shown in Table 1.
- Comparative Example 2 The recovery efficiency of the acid-fast bacterium's nucleic acid was displayed in the same manner as in Example 2 except that the pore diameter of the continuous pore structure (4) was changed to 5 ⁇ m. The results are shown in Table 1.
- Comparative Example 3 The recovery efficiency of acid-fast bacterium nucleic acids was displayed in the same manner as in Example 2 except that milliQ water was used instead of the chaotropic salt solution of (2). The results are shown in Table 1.
- Comparative Example 4 The recovery efficiency of the acid-fast bacterium's nucleic acid was displayed in the same manner as in Example 2 except that the number of suction / discharge in the acid-fast bacterium lysis and nucleic acid separation step was changed to 1. The results are shown in Table 1.
- the method of the present invention can efficiently perform lysis of mycobacteria and its nucleic acid, which were difficult to lyse due to a strong cell wall, simultaneously and at low cost and safely by a simple operation, tuberculosis This is extremely useful for pretreatment of genetic testing of bacteria.
- SEQ ID NO: 1 is the designed polynucleotide sequence described as Oligo 1 in the Examples.
- SEQ ID NO: 2 is the designed polynucleotide sequence described as Oligo 2 in the Examples.
- SEQ ID NO: 3 is the sequence of the designed polynucleotide described as Oligo 3 in the Examples.
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
本発明は、結核菌に代表される抗酸菌の溶菌とその核酸の分離を簡便な操作で同時に行う方法に関する。 The present invention relates to a method for simultaneously performing lysis of acid-fast bacteria typified by Mycobacterium tuberculosis and separation of its nucleic acids by simple operations.
結核は、日本でも復活の兆しを見せている細菌性疾患であり、その診断方法の改良は、極めて重要である。結核の診断方法としては、近年、数週間もの時間のかかる培養検査に代わって、短時間で高精度の結果が得られる遺伝子検査が行われるようになっている。 Tuberculosis is a bacterial disease that is showing signs of rebirth in Japan, and improvement of its diagnostic method is extremely important. As a method for diagnosing tuberculosis, in recent years, a genetic test that can obtain highly accurate results in a short time has been carried out instead of a culture test that takes several weeks.
結核の遺伝子検査は、結核菌の遺伝子に特異的なプライマーを使用したPCRにより、喀痰試料中の結核菌の存在を同定することによって行われる。遺伝子検査を行うには、前処理として、試料中の検査対象の菌細胞を溶菌(破壊)し、次いでその核酸を分離することが必要である。 Tuberculosis genetic testing is performed by identifying the presence of M. tuberculosis in sputum samples by PCR using primers specific to the M. tuberculosis gene. In order to perform a genetic test, as a pretreatment, it is necessary to lyse (destroy) the bacterial cells to be tested in the sample and then to separate the nucleic acid.
しかし、結核菌に代表される抗酸菌は、ミコール酸の脂質層を含む強固な細胞壁を持つため、大腸菌などの一般的な細菌と比較して溶菌が困難である。 However, acid-fast bacteria typified by Mycobacterium tuberculosis have a strong cell wall including a lipid layer of mycolic acid, and are therefore difficult to lyse compared with general bacteria such as Escherichia coli.
抗酸菌の一般的な溶菌方法としては、超音波を使用して物理的に菌細胞を破壊する方法(特許文献1参照)、フェノールを溶菌剤として使用して菌細胞を破壊する方法、60~100℃に加熱することで抗酸菌を溶菌する方法(特許文献2参照)が挙げられる。 As a general lysis method of acid-fast bacteria, a method of physically destroying bacterial cells using ultrasonic waves (see Patent Document 1), a method of destroying bacterial cells using phenol as a lysis agent, 60 A method of lysing acid-fast bacteria by heating to ˜100 ° C. (see Patent Document 2).
これらの従来公知の抗酸菌の溶菌方法は、費用がかかったり、操作が煩雑であったり、安全性に欠けたり、溶菌効率が低かったりするという問題を有し、いずれも満足できるものではなかった。また、これらの方法は抗酸菌の溶菌後に別途その核酸の分離操作を行うことを必要とするので、操作全体が煩雑であるという問題があった。 These conventionally known mycobacterial lysis methods are problematic in that they are expensive, complicated to operate, lack of safety, and have low lysis efficiency. It was. In addition, these methods require a separate operation for separating the nucleic acid after lysis of the acid-fast bacterium, so that the entire operation is complicated.
本発明は、かかる従来技術の現状に鑑み創案されたものであり、その目的は、簡便な操作で効率的に抗酸菌の溶菌とその核酸の分離を同時に行うことができる方法を提供することにある。 The present invention was devised in view of the current state of the prior art, and an object of the present invention is to provide a method capable of efficiently simultaneously lysing mycobacterial lysis and its nucleic acid with a simple operation. It is in.
本発明者は、上記目的を達成するために鋭意検討した結果、まず、抗酸菌をカオトロピック塩と接触させて菌の細胞壁を柔らかくした後、これを特定の細孔径の細孔構造連続体内を繰り返し通過させることにより、細胞壁が効率的に破壊され、抗酸菌の溶菌と核酸の分離を同時に行うことができることを見出し、本発明の完成に至った。 As a result of intensive studies to achieve the above-mentioned object, the present inventor first brought an acid-fast bacterium into contact with a chaotropic salt to soften the cell wall of the bacterium, and this was then passed through a pore structure continuum having a specific pore size. By repeatedly passing the cells, the cell wall was efficiently destroyed, and it was found that lysis of acid-fast bacteria and separation of nucleic acids could be performed simultaneously, and the present invention was completed.
本発明は、以下の(1)~(6)の構成を有するものである。
(1)カオトロピック塩と抗酸菌を含む混合液を調製し、次に細孔径10~100μmの細孔構造連続体を内部に溶着したチップを使用して前記混合液の吸引及び吐出を繰り返すことによって抗酸菌の溶菌とその核酸の分離を同時に行うことを特徴とする方法。
(2)混合液中のカオトロピック塩の濃度が2~6Mであることを特徴とする(1)に記載の方法。
(3)混合液のpHが4.5~6.5であることを特徴とする(1)または(2)に記載の方法。
(4)混合液の温度を35~80℃にして混合液の吸引及び吐出を繰り返すことを特徴とする(1)~(3)のいずれか一項に記載の方法。
(5)吸引及び吐出の繰り返しが3回以上であることを特徴とする(1)~(4)のいずれか一項に記載の方法。
(6)混合液が0.1~1.0Mの濃度の酢酸塩をさらに含むことを特徴とする(1)~(5)のいずれか一項に記載の方法。
(7)混合液が0.05~0.5Mの濃度のグッドの緩衝液をさらに含み、この緩衝液がpH4.5~6.5に緩衝pH範囲を有することを特徴とする(1)~(5)のいずれか一項に記載の方法。
The present invention has the following configurations (1) to (6).
(1) Prepare a mixed solution containing a chaotropic salt and acid-fast bacteria, and then repeat the suction and discharge of the mixed solution using a chip in which a pore structure continuous body having a pore size of 10 to 100 μm is welded. A method comprising simultaneously lysing acid-fast bacilli and separating nucleic acids thereof.
(2) The method according to (1), wherein the concentration of the chaotropic salt in the mixed solution is 2 to 6M.
(3) The method according to (1) or (2), wherein the pH of the mixed solution is 4.5 to 6.5.
(4) The method according to any one of (1) to (3), wherein the temperature of the mixed solution is set to 35 to 80 ° C., and the suction and discharge of the mixed solution are repeated.
(5) The method according to any one of (1) to (4), wherein the suction and discharge are repeated three or more times.
(6) The method according to any one of (1) to (5), wherein the mixed solution further contains acetate having a concentration of 0.1 to 1.0M.
(7) The mixed solution further includes a Good buffer solution having a concentration of 0.05 to 0.5 M, and the buffer solution has a buffer pH range of pH 4.5 to 6.5. The method according to any one of (5).
本発明の方法は、特定の細孔径の細孔構造連続体を内部に溶着したチップ内に、カオトロピック塩で細胞壁が柔らかくなった抗酸菌を繰り返し通過させるようにしているので、抗酸菌の溶菌とその核酸の分離を同時に簡単に効率的に行うことができる。 In the method of the present invention, the acid-fast bacterium having a cell wall softened with a chaotropic salt is repeatedly passed through a chip in which a continuous pore structure having a specific pore size is welded. Lysis and its nucleic acid can be separated easily and efficiently at the same time.
以下、本発明の方法を詳細に説明する。
本発明の方法は、特定の細孔径の細孔構造連続体を内部に溶着したチップを使用してカオトロピック塩と抗酸菌を含む混合液の吸引及び吐出を繰り返すことによって抗酸菌の溶菌とその核酸の分離を同時に行うことを特徴とするものである。
Hereinafter, the method of the present invention will be described in detail.
The method of the present invention uses acid-resistant bacteria lysis by repeating suction and discharge of a mixed solution containing a chaotropic salt and acid-fast bacteria using a chip in which a continuous pore structure having a specific pore size is welded. The nucleic acids are separated at the same time.
本発明の方法の溶菌対象となる抗酸菌としては、例えば、鳥型結核菌(Mycobacterium avium)、エム・イントラセルラレエ(M.intracellularae)、エム・ゴルドネエ(M.gordonae)、ヒト型結核菌(M.tuberculosis)、エム・カンサシイ(M.kansasii)、エム・フォルツイツム(M.fortuitum)、エム・ケロネエ(M.chelonae)、ウシ型結核菌(M.bovis)、エム・スクロフラセウム(M.scrofulaceum)、パラ結核菌(M.paratuberculosis)、チモテ菌(M.phlei)、エム・マリヌム(M.marinum)、エム・シミエー(M.simiae)、エム・スクロフラセウム(M.scrofulaceum)、エム・スズルガイ(M.szulgai)、らい菌(M.leprae)、エム・キセノピ(M.xenopi)、エム・ウルセランス(M.ulcerans)、鼠らい菌(M.lepraemurium)、エム・フラベセンス(M.flavescens)、エム・テレエ(M.terrae)、エム・ノンクロモジェニクム(M.nonchromogenicum)、エム・マルメンス(M.malmoense)、エム・アシアティクム(M.asiaticum)、エム・ヴァケエ(M.vaccae)、エム・ガストリ(M.gastri)、エム・トリビアル(M.triviale)、エム・ヘモフィラム(M.haemophilum)、エム・アフリカヌム(M.africanum)、エム・サーモレジスタブル(M.thermoresistable)及びスメグマ菌(M.smegmatis)を挙げることができる。 Examples of acid-fast bacteria to be lysed by the method of the present invention include Mycobacterium avium, M. intracellulare, M. gordonae, and M. tuberculosis. (M. tuberculosis), M. kansasii, M. fortuitum, M. chelonae, M. bovis, M. scroflace. ), M. paratuberculosis, M. phlei, M. marinum, M. simiae, M. scraceum (M. scr). fulaceum, M. szulgai, M. leprae, M. xenopi, M. ulcerans, M. lepraemurium, M. flavescens (M. flavescens), M. terrae, M. nonchromogenicum, M. malmoense, M. asiaticum, M. vaquee (M) Vaccae), M. gastri, M. triviale, M. haemophilum, M. africanum, e. - it can be mentioned thermo register table (M.thermoresistable) and M. smegmatis (M. smegmatis).
本発明の方法で使用されるカオトロピック塩は、タンパク質などの分子構造を不安定化する性質を持つ化学物質であり、生化学の分野において核酸抽出の際に細胞を溶解させる溶菌剤として使用される物質である。カオトロピック塩としては、従来公知のいかなるものも使用することができ、例えば、グアニジン塩、イソチアン酸ナトリウム、ヨウ化ナトリウム、ヨウ化カリウム、尿素、臭化ナトリウム、臭化カリウム、臭化カルシウム、臭化アンモニウム、過塩素酸ナトリウム、チオシアン酸ナトリウム、チオシアン酸カリウム、アンモニウムイソチオシアネート、塩化ナトリウム、塩化カリウム、塩化アンモニウムであることができる。これらの中でも、細胞溶解性と核酸回収効率の点からグアニジン塩が好ましい。グアニジン塩としては、塩酸グアニジン、グアニジンチオシアン酸塩(チオシアン酸グアニジン)、グアニジン硫酸塩、イソチオシアン酸グアニジンが挙げられ、これらの中でも、溶菌効率の点から塩酸グアニジンまたはグアニジンチオシアン酸塩が好ましい。これらの塩は、単独で用いても複数組合わせて用いてもよい。 The chaotropic salt used in the method of the present invention is a chemical substance that has the property of destabilizing molecular structures such as proteins, and is used as a lysing agent for lysing cells during nucleic acid extraction in the field of biochemistry. It is a substance. Any conventionally known chaotropic salt can be used, such as guanidine salt, sodium isothiocyanate, sodium iodide, potassium iodide, urea, sodium bromide, potassium bromide, calcium bromide, bromide. It can be ammonium, sodium perchlorate, sodium thiocyanate, potassium thiocyanate, ammonium isothiocyanate, sodium chloride, potassium chloride, ammonium chloride. Among these, a guanidine salt is preferable in terms of cell solubility and nucleic acid recovery efficiency. Examples of the guanidine salt include guanidine hydrochloride, guanidine thiocyanate (guanidine thiocyanate), guanidine sulfate, and guanidine isothiocyanate. Among these, guanidine hydrochloride or guanidine thiocyanate is preferable from the viewpoint of lysis efficiency. These salts may be used alone or in combination.
抗酸菌とカオトロピック塩は両者を含む混合液の状態で使用され、カオトロピック塩と抗酸菌を水や緩衝液などの適当な溶媒に溶解することによって容易に混合液に調製することができる。例えばカオトロピック塩と緩衝剤を脱イオン水に溶解させ、これに抗酸菌を一定濃度に調製した菌液を添加することにより、混合液を調製することができる。 The acid-fast bacterium and the chaotropic salt are used in the form of a mixed solution containing both, and can be easily prepared into a mixed solution by dissolving the chaotropic salt and the acid-fast bacterium in an appropriate solvent such as water or a buffer solution. For example, a mixed solution can be prepared by dissolving a chaotropic salt and a buffering agent in deionized water and adding a bacterial solution in which acid-fast bacteria are prepared at a constant concentration.
混合液中のカオトロピック塩の濃度は、2~6M(mol/L)であることが好ましく、さらに好ましくは3~5M(mol/L)である。混合液中のカオトロピック塩の濃度が上記下限未満では、抗酸菌細胞壁の溶解効率が低下するおそれがあり、また、上記上限を超えると、カオトロピック塩が析出するおそれがある。 The concentration of the chaotropic salt in the mixed solution is preferably 2 to 6 M (mol / L), more preferably 3 to 5 M (mol / L). If the concentration of the chaotropic salt in the mixed solution is less than the lower limit, the lysis efficiency of the acid-fast bacterium cell wall may be reduced, and if it exceeds the upper limit, the chaotropic salt may be precipitated.
混合液のpHは、4.5~6.5であることが好ましく、さらに好ましくは5.0~6.0である。混合液のpHが上記下限未満になるかまたは上記上限を超えると、核酸の分離効率が低下するおそれがある。 The pH of the mixed solution is preferably 4.5 to 6.5, more preferably 5.0 to 6.0. If the pH of the mixed solution is less than the above lower limit or exceeds the above upper limit, the nucleic acid separation efficiency may be lowered.
混合液のpHを上述の範囲に維持するためには、溶液に適当な緩衝剤を添加することが好ましい。かかる緩衝剤の一例として、酢酸塩を挙げることができる。酢酸塩の中でも、酢酸カリウム、酢酸ナトリウムなどの一価の金属の酢酸塩が特に効果的である。これらの酢酸塩の混合液中の濃度は、0.1~1.0M(mol/L)であることが緩衝効果の点で好ましい。また、かかる緩衝剤の別の例として、MES(2-モルホリノエタンスルホン酸)、ACES(N-(2-アセトアミド)-2-アミノエタンスルホン酸)、PIPES(ピペラジン-1,4-ビス(2-エタンスルホン酸))などの酸性側に緩衝能を持つグッドの緩衝液を挙げることができる。これらのグッドの緩衝液の混合液中の濃度は、0.05~0.5M(mol/L)であることが緩衝効果の点で好ましい。 In order to maintain the pH of the mixed solution in the above range, it is preferable to add an appropriate buffer to the solution. An example of such a buffering agent is acetate. Among the acetates, monovalent metal acetates such as potassium acetate and sodium acetate are particularly effective. The concentration of these acetates in the mixed solution is preferably 0.1 to 1.0 M (mol / L) from the viewpoint of the buffering effect. As another example of such a buffer, MES (2-morpholinoethanesulfonic acid), ACES (N- (2-acetamido) -2-aminoethanesulfonic acid), PIPES (piperazine-1,4-bis (2) -Good buffer solutions having a buffer capacity on the acidic side, such as ethanesulfonic acid)). The concentration of these Good buffers in the mixed solution is preferably 0.05 to 0.5 M (mol / L) from the viewpoint of the buffering effect.
本発明の方法では、カオトロピック塩と抗酸菌を含む混合液をそのまま常温で使用することも可能であるが、特定の温度に加熱して使用することが好ましい。加熱温度は、35~80℃であり、好ましくは40~75℃である。加熱すると、カオトロピック塩の溶解効果が向上しやすいが、加熱温度が高すぎると、液の蒸発が増加し、カオトロピック塩の濃度変化が生じるおそれがある。また、細孔構造連続体への核酸の吸着能が低下するおそれがある。 In the method of the present invention, a mixed solution containing a chaotropic salt and an acid-fast bacterium can be used as it is at room temperature, but it is preferable to use it after heating to a specific temperature. The heating temperature is 35 to 80 ° C., preferably 40 to 75 ° C. When heated, the dissolution effect of the chaotropic salt is likely to be improved, but if the heating temperature is too high, the evaporation of the liquid increases and the concentration of the chaotropic salt may change. In addition, the nucleic acid adsorption ability to the pore structure continuum may be reduced.
加熱方法としては、特に限定されないが、混合液を適当なチューブに入れ、ヒートブロック、ウォーターバス、マイクロウェーブオーブン、エアーバス等の公知の加熱手段で加熱する方法が挙げられる。抗酸菌は、最初から混合液に添加しておいてもよいし、混合液が所定の温度に加熱されてから添加してもよい。 The heating method is not particularly limited, and examples thereof include a method in which the mixed solution is put in an appropriate tube and heated by a known heating means such as a heat block, a water bath, a microwave oven, or an air bath. The acid-fast bacterium may be added to the mixed solution from the beginning, or may be added after the mixed solution is heated to a predetermined temperature.
本発明の方法は、細孔径10~100μmの細孔構造連続体を内部に溶着したチップを使用して上記の混合液を繰り返し吸引及び吐出することにより、抗酸菌と細孔構造連続体内の細孔が接触し、抗酸菌の溶菌だけでなく、その核酸の分離も同時に行うことを特徴とする。 The method of the present invention uses the tip having a pore structure continuous body having a pore diameter of 10 to 100 μm welded therein to repeatedly suck and discharge the above mixed solution, whereby the acid-fast bacteria and the pore structure continuous body are The pores are in contact with each other, and not only the acid-fast bacteriolysis but also the nucleic acid separation is performed at the same time.
本発明の方法で使用するチップの構造の一例の概略図を図1に示す。本発明で使用するチップ1は、基本的に従来公知の構成(例えば図1に示す細長い逆円錐形状の中空体)を有するが、その内部が先端部から一定の長さにわたって細孔構造連続体2を溶着していることを特徴とする。細孔構造連続体は、連続した細孔構造を有するものであり、その細孔径は10~100μm、好ましくは20~70μmである。細孔径が上記範囲から逸脱すると、抗酸菌の溶菌と核酸の分離を効果的に行うことができない。細孔構造体の材質は特に限定されないが、シリカが好ましい。そのような構造体は「モノリスシリカ」または「シリカモノリス」とも呼ばれている。モノリスシリカは、三次元ネットワーク状の骨格と細孔流路を一体化した構造を持ち、しかも合成の際にミクロサイズの貫通孔、及び骨格表面のナノサイズの細孔を制御することができる特性を有する。
FIG. 1 shows a schematic diagram of an example of the structure of a chip used in the method of the present invention. The
細孔構造連続体は一般的にゾル-ゲル法で製造されることができ、例えば金属アルコキシドを部分的に加水分解して反応性モノマーを作り、このモノマーを重縮合してコロイド状オリゴマーを作ってゾルを生成し、さらに加水分解して重合と架橋を促進させ、三次元構造を作ってゲルを生成することにより製造されることができる。細孔構造連続体は、チップ内部に収納されるサイズに整形された後、例えば超音波を使用してチップ内部に溶着される。 The pore structure continuum can generally be produced by a sol-gel method. For example, a metal alkoxide is partially hydrolyzed to produce a reactive monomer, and this monomer is polycondensed to produce a colloidal oligomer. Can be produced by forming a sol, further hydrolyzing to promote polymerization and crosslinking, and forming a three-dimensional structure to form a gel. The pore structure continuous body is shaped into a size accommodated in the chip, and then welded to the chip using, for example, ultrasonic waves.
細孔構造連続体を内部に溶着したチップは、シリンジなどに装着されてカオトロピック塩と抗酸菌を含む混合液の吸引及び吐出を繰り返す。吸引及び吐出の繰り返し回数は3回以上が好ましい。3回未満では、抗酸菌の溶菌と核酸の分離を十分に果たすことができないおそれがある。繰り返し回数に上限はないが、最大20回程度すれば十分である。 The chip with the pore structure continuous body welded inside is attached to a syringe and the like, and repeatedly sucks and discharges the liquid mixture containing the chaotropic salt and acid-fast bacteria. The number of repetitions of suction and discharge is preferably 3 times or more. If it is less than 3 times, there is a possibility that acid-fast lysis and nucleic acid cannot be sufficiently separated. There is no upper limit to the number of repetitions, but a maximum of about 20 is sufficient.
以下、本発明を実施例によりさらに具体的に説明するが、本発明は、これらの実施例に限定されるものではない。 Hereinafter, the present invention will be described more specifically with reference to examples. However, the present invention is not limited to these examples.
実施例1
(1)抗酸菌の準備
抗酸菌としては、ウシ型結核菌Mycobacterium bovis BCG株(以下、BCG株と略す)を使用した。BCG株を3%小川培地(日水製薬製)中で35℃で2週間培養した後、抗酸菌培養用の液体培地であるMycoBroth(極東製薬工業製)に接種し、37℃で6日間さらに培養した。分散性の高い菌液を得るため、培養後の液体培地を孔径5μmの親水性フィルターでろ過した後、濁度計でOD600を測定しながら、マクファーランド比濁法に従ってマクファーランド1の濃度に菌液を調整した。次に、液体培地中に既に遊離している核酸を除去するため、この菌液1.0mLを1.5mLのチューブに加え、遠心分離操作で菌体だけを沈殿させ、上清を取り除いて1.0mLのリン酸緩衝液で菌体を再懸濁させた。
Example 1
(1) Preparation of acid-fast bacterium As the acid-fast bacterium, the Mycobacterium bovis BCG strain (hereinafter abbreviated as BCG strain) was used. The BCG strain was cultured in 3% Ogawa medium (Nissui Pharmaceutical Co., Ltd.) at 35 ° C. for 2 weeks, then inoculated into MycoBroth (manufactured by Kyokuto Pharmaceutical Co., Ltd.), a liquid medium for acid-fast bacteria culture, and at 37 ° C. for 6 days. Further culture was performed. In order to obtain a highly dispersible bacterial solution, the cultured liquid medium was filtered with a hydrophilic filter having a pore size of 5 μm, and then the concentration of
(2)カオトロピック塩の溶液の準備
カオトロピック塩としてのグアニジンチオシアン酸及び緩衝剤としての酢酸カリウムを脱イオン水に溶解させ、緩衝剤を含有するカオトロピック塩の溶液を調製した。
(2) Preparation of chaotropic salt solution Guanidine thiocyanic acid as a chaotropic salt and potassium acetate as a buffering agent were dissolved in deionized water to prepare a solution of a chaotropic salt containing a buffering agent.
(3)混合液の調製
(2)で調製したカオトロピック塩の溶液500μLに、(1)で準備したマクファーランド1の菌液をリン酸緩衝液で1000倍に希釈したものを混合した。混合液中のグアニジンチオシアン酸の濃度は、5Mであり、酢酸カリウムの濃度は、0.8Mであり、溶液のpHは5.5であった。
(3) Preparation of Mixed Solution To 500 μL of the chaotropic salt solution prepared in (2), a solution obtained by diluting the
(4)抗酸菌の溶菌及び核酸の分離抽出
次に、図1に記載のような細孔構造連続体を内部に溶着したチップを使用して、混合液中の抗酸菌の溶菌とその核酸の分離抽出を行った。具体的には市販の250μLチップ内に細孔構造連続体(モノリスシリカ、細孔径30μm、切断面積3.14平方mm、厚さ1mm)を溶着したものをテルモ製の1mLシリンジに装着し、混合液を100μL/秒の速度で10回吸引および吐出し、混合液中の抗酸菌を溶菌し、その核酸をチップ中の細孔構造連続体に吸着させた。混合液を完全に出し切った後に、洗浄液500μLの入ったチューブにチップを移動させ、洗浄液を100μL/秒の速度で3回吸引および吐出して洗浄した。この洗浄工程をもう一度繰り返した。最後に溶出液100μLの入ったチューブにチップを移動させ、溶出液を100μL/秒の速度で5回吸引および吐出して、チップ中の細孔構造連続体に吸着した抗酸菌の核酸を溶出した。溶出効率の低下を抑えるため、吸引および吐出の間は、チップ内の細孔構造連続体に空気が接触しないように注意した。なお、洗浄液としては、70%エタノール中の0.8M酢酸カリウム溶液を使用し、溶出液としては、10mM水酸化カリウム水溶液を使用した。
(4) Lysis of acid-fast bacteria and separation and extraction of nucleic acid Next, using a chip having a pore structure continuous body as shown in FIG. Nucleic acid was separated and extracted. Specifically, a porous structure continuous body (monolith silica, pore diameter 30 μm, cutting area 3.14 square mm,
(5)リアルタイムPCRによる、抗酸菌遺伝子の検出及び定量
次に、(4)で得た核酸溶出液を対象として、リアルタイムPCRにより抗酸菌遺伝子の検出及び定量を行った。PCRの試薬組成、並びにPCR条件は、以下に示す通りであった。
(5) Detection and quantification of acid-fast bacterium genes by real-time PCR Next, the acid-fast bacterium genes were detected and quantified by real-time PCR for the nucleic acid eluate obtained in (4). The PCR reagent composition and PCR conditions were as shown below.
試薬組成:
オリゴ1 250nM、
オリゴ2 1500nM、
オリゴ3(5’末端をBODIPY-FL標識されている)250nM、
×10緩衝液 1μL、
dNTP 0.2mM、
MgSO4 4mM、
KOD plus DNAポリメラーゼ 0.2U、
溶出液 1μL
(ミリQ水で全量を10μLに調整する)
(オリゴ1~オリゴ3の配列は、配列表の配列番号1~3に示される通りである。)
Reagent composition:
Oligo 3 (5 ′ end labeled with BODIPY-FL) 250 nM,
× 10
dNTP 0.2 mM,
MgSO 4 4 mM,
KOD plus DNA polymerase 0.2U,
Eluate 1μL
(Adjust the total volume to 10 μL with Milli-Q water)
(The sequences of
PCR条件:
熱変性:94℃・2分、98℃・0秒、アニーリング:60℃・5秒(蛍光検出)、50サイクル
PCR conditions:
Thermal denaturation: 94 ° C for 2 minutes, 98 ° C for 0 seconds, annealing: 60 ° C for 5 seconds (fluorescence detection), 50 cycles
上記試薬組成は、BCG株を特異的に検出できるプライマーとプローブの組み合わせである。陽性コントロールとして、BCG株からフェノール・クロロホルム法で抽出したゲノムDNAを10mMトリス緩衝液で1μL中に1000コピー含むように希釈したものを使用した。リアルタイムPCRは、増幅産物とプローブがハイブリダイゼーションするとプローブに標識された蛍光色素の蛍光が消光することに基づいてサンプル中の特定の核酸配列を検出するものである。核酸の増幅及び検出には、ロシュ・ダイアグノスティック社製ライトサイクラー(登録商標)を使用した。測定モードは、530nmを利用し、得られたリアルタイム検出データを利用して、アニーリング時のQProbe消光率を算出した。さらに、消光率2%に達したサイクル数を求めて、SYBR Green Iを用いたリアルタイム定量PCR法と同様にして解析を行った。抗酸菌の核酸の回収効率は、陽性コントロールを100%としてそれに対する百分率で表示した。なお、抗酸菌の核酸の回収効率は、30%以上であれば良好と考えられる。結果を表1に示す。 The above reagent composition is a combination of a primer and a probe that can specifically detect the BCG strain. As a positive control, genomic DNA extracted from the BCG strain by the phenol / chloroform method was diluted with 10 mM Tris buffer so as to contain 1000 copies in 1 μL. Real-time PCR detects a specific nucleic acid sequence in a sample based on the fact that the fluorescence of a fluorescent dye labeled on the probe is quenched when the amplification product and the probe are hybridized. A light cycler (registered trademark) manufactured by Roche Diagnostics was used for amplification and detection of nucleic acids. As the measurement mode, 530 nm was used, and the obtained QProbe extinction ratio was calculated using the obtained real-time detection data. Furthermore, the number of cycles that reached a quenching rate of 2% was determined and analyzed in the same manner as the real-time quantitative PCR method using SYBR Green I. The nucleic acid recovery efficiency of mycobacteria was expressed as a percentage relative to 100% positive control. In addition, it is considered that the nucleic acid recovery efficiency of acid-fast bacteria is good if it is 30% or more. The results are shown in Table 1.
実施例2
(3)で得た混合液を1.5mLのスクリュー付蓋のあるチューブに入れ、ヒートブロック上で65℃で5分間加熱したものを使用して(4)で吸引及び吐出を行った以外は、実施例1と同様にして、抗酸菌の核酸の回収効率を表示した。結果を表1に示す。
Example 2
The mixture obtained in (3) was put into a 1.5 mL tube with a screw cap and heated and heated at 65 ° C. for 5 minutes on a heat block, except that suction and discharge were performed in (4). In the same manner as in Example 1, the nucleic acid recovery efficiency of acid-fast bacteria was displayed. The results are shown in Table 1.
実施例3
(4)の細孔構造連続体の細孔径を10μmに変更した以外は、実施例2と同様にして、抗酸菌の核酸の回収効率を表示した。結果を表1に示す。
Example 3
The recovery efficiency of acid-fast bacilli nucleic acids was displayed in the same manner as in Example 2 except that the pore diameter of the pore structure continuum of (4) was changed to 10 μm. The results are shown in Table 1.
実施例4
(4)の細孔構造連続体の細孔径を20μmに変更した以外は、実施例2と同様にして、抗酸菌の核酸の回収効率を表示した。結果を表1に示す。
Example 4
The recovery efficiency of acid-fast bacterium nucleic acids was displayed in the same manner as in Example 2 except that the pore diameter of the pore structure continuum in (4) was changed to 20 μm. The results are shown in Table 1.
実施例5
(4)の細孔構造連続体の細孔径を40μmに変更した以外は、実施例2と同様にして、抗酸菌の核酸の回収効率を表示した。結果を表1に示す。
Example 5
The recovery efficiency of acid-fast bacterium nucleic acids was displayed in the same manner as in Example 2 except that the pore diameter of the pore structure continuum in (4) was changed to 40 μm. The results are shown in Table 1.
実施例6
(4)の細孔構造連続体の細孔径を50μmに変更した以外は、実施例2と同様にして、抗酸菌の核酸の回収効率を表示した。結果を表1に示す。
Example 6
The nucleic acid recovery efficiency of acid-fast bacteria was displayed in the same manner as in Example 2 except that the pore diameter of the pore structure continuous body of (4) was changed to 50 μm. The results are shown in Table 1.
実施例7
(4)の細孔構造連続体の細孔径を70μmに変更した以外は、実施例2と同様にして、抗酸菌の核酸の回収効率を表示した。結果を表1に示す。
Example 7
The recovery efficiency of acid-fast bacilli nucleic acids was displayed in the same manner as in Example 2 except that the pore diameter of the pore structure continuum in (4) was changed to 70 μm. The results are shown in Table 1.
実施例8
カオトロピック塩としてグアニジンチオシアン酸の代わりに塩酸グアニジンを使用した以外は、実施例2と同様にして、抗酸菌の核酸の回収効率を表示した。結果を表1に示す。
Example 8
The efficiency of acid-fast bacilli nucleic acid recovery was displayed in the same manner as in Example 2, except that guanidine hydrochloride was used in place of guanidine thiocyanate as the chaotropic salt. The results are shown in Table 1.
実施例9
抗酸菌の溶菌及びその核酸の分離の工程での吸引・吐出回数を5回に変更した以外は、実施例2と同様にして、抗酸菌の核酸の回収効率を表示した。結果を表1に示す。
Example 9
The recovery efficiency of the acid-fast bacterium's nucleic acid was displayed in the same manner as in Example 2 except that the number of suction / discharge in the process of lysis of the acid-fast bacterium and the separation of the nucleic acid was changed to 5. The results are shown in Table 1.
実施例10
抗酸菌の溶菌及びその核酸の分離の工程での吸引・吐出回数を20回に変更した以外は、実施例2と同様にして、抗酸菌の核酸の回収効率を表示した。結果を表1に示す。
Example 10
The recovery efficiency of acid-fast bacilli nucleic acids was displayed in the same manner as in Example 2 except that the number of suction / discharge in the acid-fast bacilli lysis and nucleic acid separation steps was changed to 20. The results are shown in Table 1.
実施例11
加熱温度を40℃に変更した以外は、実施例2と同様にして、抗酸菌の核酸の回収効率を表示した。結果を表1に示す。
Example 11
The recovery efficiency of the acid-fast bacterium nucleic acid was displayed in the same manner as in Example 2 except that the heating temperature was changed to 40 ° C. The results are shown in Table 1.
実施例12
加熱温度を75℃に変更した以外は、実施例2と同様にして、抗酸菌の核酸の回収効率を表示した。結果を表1に示す。
Example 12
The recovery efficiency of acid-fast bacilli nucleic acids was displayed in the same manner as in Example 2 except that the heating temperature was changed to 75 ° C. The results are shown in Table 1.
実施例13
加熱温度を95℃に変更した以外は、実施例2と同様にして、抗酸菌の核酸の回収効率を表示した。結果を表1に示す。
Example 13
The recovery efficiency of acid-fast bacterium nucleic acids was displayed in the same manner as in Example 2 except that the heating temperature was changed to 95 ° C. The results are shown in Table 1.
比較例1
(4)の細孔構造連続体の細孔径を120μmに変更した以外は、実施例2と同様にして、抗酸菌の核酸の回収効率を表示した。結果を表1に示す。
Comparative Example 1
The nucleic acid recovery efficiency of acid-fast bacteria was displayed in the same manner as in Example 2 except that the pore diameter of the pore structure continuous body of (4) was changed to 120 μm. The results are shown in Table 1.
比較例2
(4)の細孔構造連続体の細孔径を5μmに変更した以外は、実施例2と同様にして、抗酸菌の核酸の回収効率を表示した。結果を表1に示す。
Comparative Example 2
The recovery efficiency of the acid-fast bacterium's nucleic acid was displayed in the same manner as in Example 2 except that the pore diameter of the continuous pore structure (4) was changed to 5 μm. The results are shown in Table 1.
比較例3
(2)のカオトロピック塩の溶液の代わりにミリQ水を使用した以外は、実施例2と同様にして、抗酸菌の核酸の回収効率を表示した。結果を表1に示す。
Comparative Example 3
The recovery efficiency of acid-fast bacterium nucleic acids was displayed in the same manner as in Example 2 except that milliQ water was used instead of the chaotropic salt solution of (2). The results are shown in Table 1.
比較例4
抗酸菌の溶菌及びその核酸の分離の工程での吸引・吐出回数を1回に変更した以外は、実施例2と同様にして、抗酸菌の核酸の回収効率を表示した。結果を表1に示す。
Comparative Example 4
The recovery efficiency of the acid-fast bacterium's nucleic acid was displayed in the same manner as in Example 2 except that the number of suction / discharge in the acid-fast bacterium lysis and nucleic acid separation step was changed to 1. The results are shown in Table 1.
表1から、特定の細孔径の細孔構造連続体を内部に溶着したチップを使用して吸引及び吐出を繰り返した実施例1~13では、本発明の細孔径の範囲外の細孔構造連続体で処理された比較例1及び2、カオトロピック塩の溶液を使用しなかった比較例3、並びに吸引及び吐出を繰り返さなかった比較例4と比較して、核酸の回収効率が顕著に高いことが理解できる。 From Table 1, in Examples 1 to 13 in which suction and discharge were repeated using a chip in which a pore structure continuous body having a specific pore diameter was welded, pore structure continuous outside the pore diameter range of the present invention. Compared with Comparative Examples 1 and 2, which were treated with the body, Comparative Example 3 in which the solution of chaotropic salt was not used, and Comparative Example 4 in which the suction and discharge were not repeated, the nucleic acid recovery efficiency was remarkably high. Understandable.
本発明の方法は、強固な細胞壁のために溶菌が困難であった抗酸菌の溶菌とその核酸の分離を同時に効率良く、しかも簡便な操作で低コストかつ安全に行うことができるので、結核菌の遺伝子検査の前処理などに極めて有用である。 Since the method of the present invention can efficiently perform lysis of mycobacteria and its nucleic acid, which were difficult to lyse due to a strong cell wall, simultaneously and at low cost and safely by a simple operation, tuberculosis This is extremely useful for pretreatment of genetic testing of bacteria.
配列番号1は、実施例でオリゴ1として記載した設計されたポリヌクレオチドの配列である。
配列番号2は、実施例でオリゴ2として記載した設計されたポリヌクレオチドの配列である。
配列番号3は、実施例でオリゴ3として記載した設計されたポリヌクレオチドの配列である。
SEQ ID NO: 1 is the designed polynucleotide sequence described as
SEQ ID NO: 2 is the designed polynucleotide sequence described as
SEQ ID NO: 3 is the sequence of the designed polynucleotide described as Oligo 3 in the Examples.
Claims (7)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012520447A JP5773280B2 (en) | 2010-06-18 | 2011-06-14 | Method for simultaneous lysis of mycobacteria and separation of its nucleic acids |
| CN2011800301817A CN102947449A (en) | 2010-06-18 | 2011-06-14 | Method for simultaneous achievement of bacteriolysis of acid-fast bacterium and separation of nucleic acid from the bacterium |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010139368 | 2010-06-18 | ||
| JP2010-139368 | 2010-06-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2011158815A1 true WO2011158815A1 (en) | 2011-12-22 |
Family
ID=45348214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2011/063555 Ceased WO2011158815A1 (en) | 2010-06-18 | 2011-06-14 | Method for simultaneous achievement of bacteriolysis of acid-fast bacterium and separation of nucleic acid from the bacterium |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP5773280B2 (en) |
| CN (1) | CN102947449A (en) |
| WO (1) | WO2011158815A1 (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06319527A (en) * | 1991-12-18 | 1994-11-22 | Becton Dickinson & Co | Bacteriolysis of mycobacteria |
| JPH11266864A (en) * | 1998-03-19 | 1999-10-05 | Hitachi Ltd | Method and apparatus for purifying nucleic acid |
| WO2002078846A1 (en) * | 2001-03-28 | 2002-10-10 | Hitachi, Ltd. | Instrument and method for collecting nucleic acids |
| WO2005078088A1 (en) * | 2004-02-12 | 2005-08-25 | Gl Sciences Incorporated | Mechanism of separating and purifying dna and so on |
| JP2006296220A (en) * | 2005-04-15 | 2006-11-02 | Gl Sciences Inc | Separation and purification method and separation and purification mechanism for DNA, etc. |
| JP2007306867A (en) * | 2006-05-19 | 2007-11-29 | Hitachi High-Technologies Corp | Nucleic acid extraction apparatus and nucleic acid extraction method |
| WO2009058432A1 (en) * | 2007-10-31 | 2009-05-07 | Akonni Biosystems | Sample preparation device |
| JP2011110025A (en) * | 2009-11-30 | 2011-06-09 | Toyobo Co Ltd | Method for dissolving acid fast bacteria |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4090443B2 (en) * | 2004-02-24 | 2008-05-28 | 株式会社日立ハイテクノロジーズ | Nucleic acid recovery instrument, its parts, and method of producing nucleic acid recovery instrument |
-
2011
- 2011-06-14 WO PCT/JP2011/063555 patent/WO2011158815A1/en not_active Ceased
- 2011-06-14 JP JP2012520447A patent/JP5773280B2/en active Active
- 2011-06-14 CN CN2011800301817A patent/CN102947449A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06319527A (en) * | 1991-12-18 | 1994-11-22 | Becton Dickinson & Co | Bacteriolysis of mycobacteria |
| JPH11266864A (en) * | 1998-03-19 | 1999-10-05 | Hitachi Ltd | Method and apparatus for purifying nucleic acid |
| WO2002078846A1 (en) * | 2001-03-28 | 2002-10-10 | Hitachi, Ltd. | Instrument and method for collecting nucleic acids |
| WO2005078088A1 (en) * | 2004-02-12 | 2005-08-25 | Gl Sciences Incorporated | Mechanism of separating and purifying dna and so on |
| JP2006296220A (en) * | 2005-04-15 | 2006-11-02 | Gl Sciences Inc | Separation and purification method and separation and purification mechanism for DNA, etc. |
| JP2007306867A (en) * | 2006-05-19 | 2007-11-29 | Hitachi High-Technologies Corp | Nucleic acid extraction apparatus and nucleic acid extraction method |
| WO2009058432A1 (en) * | 2007-10-31 | 2009-05-07 | Akonni Biosystems | Sample preparation device |
| JP2011110025A (en) * | 2009-11-30 | 2011-06-09 | Toyobo Co Ltd | Method for dissolving acid fast bacteria |
Non-Patent Citations (3)
| Title |
|---|
| BOOM R ET AL.: "Rapid and simple method for purification of nucleic acids", J. CLIN. MICROBIOL., vol. 28, no. 3, 1990, pages 495 - 503 * |
| O'MAHONY J ET AL.: "Rapid real-time PCR assay for detection and quantitation of Mycobacterium avium subsp. paratuberculosis DNA in artificially contaminated milk", APPL. ENVIRON. MICROBIOL., vol. 70, no. 8, 2004, pages 4561 - 4568 * |
| WILSON SM ET AL.: "Progress toward a simplified polymerase chain reaction and its application to diagnosis of tuberculosis", J. CLIN. MICROBIOL., vol. 31, no. 4, 1993, pages 776 - 782 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102947449A (en) | 2013-02-27 |
| JP5773280B2 (en) | 2015-09-02 |
| JPWO2011158815A1 (en) | 2013-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20110281272A1 (en) | Processing and analysis of viscous liquid biological samples | |
| JP6100162B2 (en) | Universal lysis buffer and processing method for lysing body samples | |
| JP2625340B2 (en) | Mycobacterial lysis method | |
| EP2854981B1 (en) | Methods of nucleic acid fractionation and detection | |
| US20110065110A1 (en) | Method For The Extraction And Purification Of Nucleic Acids On A Membrane | |
| CN111936633A (en) | Microbial isolation and detection | |
| EP1574564B1 (en) | Microorganism or cell collecting method, and microorganism or cell collecting implement used for the method | |
| US20230416722A1 (en) | Apparatus and method for pretreatment of microbial samples | |
| WO2015157650A1 (en) | Nucleic acid purification method | |
| CN104975003A (en) | Nucleic acid recovery and purification kit and method | |
| JP6525001B2 (en) | Method for recovering short strand nucleic acid | |
| JP5714291B2 (en) | Extraction and purification of mycobacterial DNA | |
| EP1730276B1 (en) | Method, chip, device and system for extraction of biological materials | |
| US9707555B2 (en) | Method for pretreatment of microbial samples | |
| JP2004180551A (en) | Method for collecting microorganism and method for amplifying or detecting gene using the same | |
| EP3347485A1 (en) | Methods for isolating microbial cells from a blood sample | |
| Flaender et al. | Grinding Lysis (GL): A microfluidic device for sample enrichment and mechanical lysis in one | |
| JP5773280B2 (en) | Method for simultaneous lysis of mycobacteria and separation of its nucleic acids | |
| JP5568968B2 (en) | Lysing method of acid-fast bacterium | |
| JP6301260B2 (en) | RNA preparation method | |
| JPWO2003097816A1 (en) | Method for lysing mycobacteria and gene amplification or detection method using the same | |
| US20050239045A1 (en) | Microorganism or cell collecting method, and microorganism or cell collecting implement used for the method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 201180030181.7 Country of ref document: CN |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11795720 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2012520447 Country of ref document: JP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 11795720 Country of ref document: EP Kind code of ref document: A1 |